Adult height in Turkish patients with Turner syndrome without growth hormone treatment.

نویسندگان

  • Abdullah Bereket
  • Serap Turan
  • Nursel Elçioğlu
  • Seniha Hacihanefioğlu
  • Nihal Memioğlu
  • Firdevs Baş
  • Rüveyde Bundak
  • Feyza Darendeliler
  • Hülya Günöz
  • Nurçin Saka
  • Oya Ercan
  • Ilknur Arslanoğlu
  • Pinar Işgüven
  • Metin Yildiz
  • Sule Can
  • Ebru Ozerkan
  • Mahmut Coker
  • Sükran Darcan
  • Behzat Ozkan
  • Zerrin Orbak
  • Sitki Oztaş
  • Sükrü Palandüz
  • Ilhan Sezgin
  • Emre Atabek
  • Ibrahim Erkul
  • Gürbüz Erdoğan
چکیده

Spontaneous adult height (AH) in Turner syndrome (TS) varies among populations. Population-specific AH data is essential to assess the efficacy of growth-promoting therapies in TS. A multicenter study was performed to establish AH of nongrowth hormone (GH)-treated Turkish patients with TS. One hundred ten patients with TS (diagnosed by karyotype) who reached AH (no growth in the previous year, or bone age > 15 years) without receiving GH treatment were included in the study. The average AH was found to be 141.6 +/- 7.0 cm at the age of 22.9 +/- 6.2 years, which is 18.4 cm below the population average and 16.4 cm below the patients' mid-parental heights. Bone age at start of estrogen replacement was 12.3 +/- 1.3 year. Karyotype distribution of the patients was 45X (43%), 45X/46XX (16%), 45X/46Xi (12%), 45XiXq (10%) and others (19%). When the patients were evaluated according to their karyotype as 45X and non-45X, no significant difference in AH was observed (142.4 +/- 6.9 cm vs 140.9 +/- 7.1 cm, respectively). Adult height of non-GH-treated Turkish TS patients obtained in this study was comparable to that of other Mediterranean populations, but shorter than that of Northern European patients. Karyotype does not seem to affect AH in TS.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Effect of oxandrolone therapy on adult height in Turner syndrome patients treated with growth hormone: a meta-analysis

Turner syndrome is a chromosomal abnormality in which there is complete or partial absence of the X chromosome. Turner syndrome effects 1 in every 2000 live births. Short stature is a cardinal feature of Turner Syndrome and the standard treatment is recombinant human growth hormone. When growth hormone is started at an early age a normal adult height can be achieved. With delayed diagnosis youn...

متن کامل

Factors predicting the response to growth hormone therapy in Taiwanese patients with Turner syndrome

Background Turner syndrome (TS) occurs in one 2000-2500 live female births and is associated with short stature, premature ovarian failure, and a range of other phenotypic features. Girls with TS achieve an average adult height 20cm shorter than their mid-parenteral height if they didn’t receive treatment. Growth hormone (GH) treatment was associated with highly significant gains in growth and ...

متن کامل

EFFEC T OF HUMAN GROWTH HORMONE TREATMEN T IN CHILDREN WI TH GROWTH HORMONE DEFICIENCY, TURNER\'S SYNDROME AND ACHONDROPLASIA: A COMPARISON OF DOSE FREQUENCY AND ROU TE OF ADMINIS1RATION

Recombinant human growth hormone (hGH) was given for 6 months or longer to 68 patients with GH deficiency, 6 with Turner's syndrome and 5 with achondroplasia, during 1986-1994 in a prospective study. The total weekly administered dose of GH was 0.6 u/kg. By random sampling, 29 of 68 GH deficient patients (42.6%) received twice weekly (2 iw) intramuscular (im) injections, 17 (25%) received ...

متن کامل

Response to three years of growth hormone therapy in girls with Turner syndrome

PURPOSE Short stature is the most common finding in patients with Turner syndrome. Improving the final adult height in these patients is a challenge both for the patients and physicians. We investigated the clinical response of patients to growth hormone treatment for height improvement over the period of three years. METHODS Review of medical records from 27 patients with Turner syndrome tre...

متن کامل

Growth hormone treatment in non-growth hormone-deficient children

Until 1985 growth hormone (GH) was obtained from pituitary extracts, and was available in limited amounts only to treat severe growth hormone deficiency (GHD). With the availability of unlimited quantities of GH obtained from recombinant DNA technology, researchers started to explore new modalities to treat GHD children, as well as to treat a number of other non-GHD conditions. Although with so...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:
  • The Turkish journal of pediatrics

دوره 50 5  شماره 

صفحات  -

تاریخ انتشار 2008